1 / 7

Lucentis Market Analysis and Forecast to 2023

RnRMarketResearch.com adds “Lucentis (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023”to its store. Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss.

Rudra1234
Télécharger la présentation

Lucentis Market Analysis and Forecast to 2023

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lucentis (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 By RnRMarketResearch Browse more reports on Pharmaceuticals athttp://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Lucentis (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Lucentis (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 Lucentis (ranibizumab) is an anti-VEGF-A monoclonal antibody (mAb) fragment developed by Genentech/Roche. It is derived from the larger parent molecule, bevacizumab, which is another anti-VEGF drug marketed as Avastin by Genentech/Roche/Chugai. It was hoped that Lucentis, as a lower-molecular-weight, humanized fragment of an immunoglobulin G1 (IgG1) mAb, would result in improved retinal penetration over Avastin, and therefore, confer superior efficacy. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Complete Report is available at http://www.rnrmarketresearch.com/lucentis-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023-market-report.html. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Lucentis (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 Scope: Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Lucentis including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for Lucentis for the top seven countries from 2013 to 2023. Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Lucentis (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 Reasons to Buy: • Understand and capitalize by identifying products that are most likely to ensure a robust return. • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration. • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential. • Make more informed business decisions from insightful and in-depth analysis of Lucentis performance. • Obtain sales forecast for Lucentis from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan). ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Lucentis (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 Table of Contents: 1 Table of Contents 6 1.1 List of Tables 8 1.2 List of Figures 8 2 Introduction 9 2.1 Related Reports 10 3 Disease Overview 12 3.1 Macular Degeneration Overview 12 3.1.1 Etiology and Pathophysiology14 3.1.2 Classification 18 3.1.3 Symptoms and Diagnosis 20 ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  7. Lucentis (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related